AR108202A1 - Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 - Google Patents
Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1Info
- Publication number
- AR108202A1 AR108202A1 ARP170100898A ARP170100898A AR108202A1 AR 108202 A1 AR108202 A1 AR 108202A1 AR P170100898 A ARP170100898 A AR P170100898A AR P170100898 A ARP170100898 A AR P170100898A AR 108202 A1 AR108202 A1 AR 108202A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- inhibitor
- ccr1
- administration
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud proporciona métodos para reducir la carga tumoral minimal, el crecimiento tumoral, el avance tumoral y/o la metástasis en un sujeto que padece un cáncer de tumor sólido como por ejemplo el cáncer de mama triple negativo. Los métodos incluyen la administración a un sujeto que lo necesite de una cantidad eficaz terapéuticamente de un inhibidor de PD-L1 o un inhibidor de PD-1 en combinación con un antagonista del receptor de quimiocinas de molécula pequeña que bloquea CCR1. Reivindicación 4: El método de cualquiera de las reivindicaciones 1 a 3, en donde el antagonista del receptor de quimiocina CCR1 tiene la fórmula (1), en donde cada A es N o CH y como mínimo una A es N; R¹ es halógeno; R³ es seleccionado del grupo que consiste en C₁₋₈ alquilo, C₃₋₈ cicloalquilo y C₂₋₈ alquenilo; y R⁸ es C₁₋₈ alquilo; o una sal del mismo aceptable farmacéuticamente. Reivindicación 25: Un equipo para el tratamiento de un sujeto que tiene un cáncer de tumor sólido, dicho equipo comprende una cantidad eficaz terapéuticamente de un antagonista del receptor de quimiocina CCR1 y una cantidad eficaz terapéuticamente de un inhibidor de PD-1 o un inhibidor de PD-L1, con instrucciones para una administración eficaz.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319689P | 2016-04-07 | 2016-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108202A1 true AR108202A1 (es) | 2018-07-25 |
Family
ID=59999231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100898A AR108202A1 (es) | 2016-04-07 | 2017-04-07 | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10568870B2 (es) |
| EP (1) | EP3439653B1 (es) |
| JP (2) | JP7539231B2 (es) |
| KR (1) | KR102370704B1 (es) |
| CN (1) | CN109310677A (es) |
| AR (1) | AR108202A1 (es) |
| AU (1) | AU2017246460B2 (es) |
| BR (1) | BR112018070361A2 (es) |
| DK (1) | DK3439653T3 (es) |
| ES (1) | ES2864148T3 (es) |
| IL (1) | IL261998B2 (es) |
| MX (1) | MX384929B (es) |
| PL (1) | PL3439653T3 (es) |
| PT (1) | PT3439653T (es) |
| RU (1) | RU2745195C2 (es) |
| SG (1) | SG11201808626WA (es) |
| TW (1) | TWI808938B (es) |
| WO (1) | WO2017176965A1 (es) |
| ZA (1) | ZA201806633B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
| CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
| KR102144658B1 (ko) * | 2017-03-29 | 2020-08-14 | 시오노기세이야쿠가부시키가이샤 | 암 치료용 의약 조성물 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| WO2019023575A1 (en) | 2017-07-28 | 2019-01-31 | Chemocentryx, Inc. | IMMUNOMODULATORY COMPOUNDS |
| JP7198269B2 (ja) | 2017-08-08 | 2022-12-28 | ケモセントリックス，インコーポレイティド | 大員環免疫調節剤 |
| RU2020124143A (ru) * | 2017-12-22 | 2022-01-24 | Кодадженикс Инк. | Рекомбинантный вирус с областью деоптимизированной пары кодонов и его применение для лечения рака |
| EP3755311B1 (en) | 2018-02-22 | 2026-01-28 | ChemoCentryx, Inc. | Indane-amines as pd-l1 antagonists |
| RU2020132280A (ru) | 2018-03-08 | 2022-04-11 | Кодадженикс Инк. | Аттенуированные флавивирусы |
| US20190380998A1 (en) | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| EP3806846A1 (en) | 2018-06-15 | 2021-04-21 | Board of Regents, The University of Texas System | Methods of treating and preventing breast cancer with s-equol |
| MA53506A (fr) * | 2018-08-29 | 2021-07-07 | Chemocentryx Inc | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| EP3853247A2 (en) | 2018-09-19 | 2021-07-28 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| SMT202400252T1 (it) | 2018-11-14 | 2024-07-09 | Regeneron Pharma | Somministrazione intralesionale di inibitori di pd-1 il trattamentodel cancro della pelle. |
| JP2022521800A (ja) | 2019-02-28 | 2022-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
| MA55204A (fr) | 2019-03-06 | 2022-01-12 | Regeneron Pharma | Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer |
| WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| WO2021046634A1 (en) * | 2019-09-11 | 2021-03-18 | Boehringer Ingelheim Io Canada, Inc. | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies |
| GB201918692D0 (en) * | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
| US20230331858A1 (en) * | 2019-12-24 | 2023-10-19 | Neoleukin Therapeutics, Inc. | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| US20210403567A1 (en) | 2020-05-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering a pd-1 inhibitor |
| CA3168743A1 (en) | 2020-08-26 | 2022-03-03 | Matthew G. Fury | Methods of treating cancer by administering a pd-1 inhibitor |
| AU2021337650A1 (en) | 2020-09-03 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer pain by administering a pd-1 inhibitor |
| EP4228627A4 (en) * | 2020-10-13 | 2024-11-06 | Board of Regents, The University of Texas System | COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATIC DUCT ADENOCARCINOMA |
| KR20230159590A (ko) | 2021-03-23 | 2023-11-21 | 리제너론 파아마슈티컬스, 인크. | Pd-1 억제제를 투여함에 의한 면역억제 또는 면역손상된 환자에서 암을 치료하는 방법 |
| US20230139492A1 (en) | 2021-07-19 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| WO2023159102A1 (en) | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
| WO2023230220A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024223299A2 (en) | 2023-04-26 | 2024-10-31 | Isa Pharmaceuticals B.V. | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor |
| US20250114468A1 (en) | 2023-10-09 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| DE19539091A1 (de) | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
| US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| AU2001290258A1 (en) | 2000-09-22 | 2002-04-02 | Nihon Nohyaku Co. Ltd. | N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
| US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| CA2524321A1 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| EP1883646A1 (en) | 2005-05-19 | 2008-02-06 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| AU2006262122B2 (en) | 2005-06-22 | 2013-01-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| FR2887450B1 (fr) | 2005-06-23 | 2007-08-24 | Rhodia Chimie Sa | Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques |
| JPWO2007026834A1 (ja) | 2005-09-01 | 2009-03-12 | クミアイ化学工業株式会社 | ピラゾール誘導体及び農園芸用除草剤 |
| US7576218B2 (en) | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | 4-phenylpiperdine-pyrazole CCR1 antagonists |
| US20090252779A1 (en) | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| WO2008045484A1 (en) | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| WO2008072724A1 (ja) | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | ピラゾール誘導体 |
| US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
| HUE032273T2 (en) | 2007-05-22 | 2017-09-28 | Chemocentryx Inc | 3-Imidazolyl-pyrazolo [3,4-b] pyridines |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| WO2009002933A1 (en) | 2007-06-22 | 2008-12-31 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| WO2009063953A1 (ja) | 2007-11-13 | 2009-05-22 | Taisho Pharmaceutical Co., Ltd. | フェニルピラゾール誘導体 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| US20120108614A1 (en) | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
| EP2323663B1 (en) * | 2008-09-11 | 2015-02-25 | ChemoCentryx, Inc. | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
| JP6087503B2 (ja) | 2008-09-26 | 2017-03-08 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途 |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| GB0915892D0 (en) | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| US9422339B2 (en) | 2012-03-29 | 2016-08-23 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds |
| EA037351B8 (ru) | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
| MY186099A (en) | 2012-05-31 | 2021-06-22 | Genentech Inc | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9181241B2 (en) * | 2012-08-27 | 2015-11-10 | Chemocentryx, Inc. | Antagonists of chemokine receptors |
| EP2928474B1 (en) * | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| DK2935227T3 (en) * | 2012-12-21 | 2017-12-04 | Chemocentryx Inc | DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| SI3021869T1 (sl) * | 2013-07-16 | 2020-10-30 | F. Hoffmann-La Roche Ag | Postopki zdravljenja raka z uporabo antagonistov in inhibitorjev TIGIT, ki se vežejo na os PD-1 |
| ES2827679T3 (es) | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib |
| KR102276644B1 (ko) | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 화합물 |
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| EA201891818A3 (ru) | 2013-09-06 | 2019-03-29 | Ауриген Дискавери Текнолоджиз Лимитед | Способ получения соединений, используемых при получении циклических пептидомиметических соединений |
| CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
| WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CA2950577A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| CN106573060A (zh) * | 2014-07-15 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
| EA034496B1 (ru) | 2014-09-11 | 2020-02-13 | Бристол-Майерс Сквибб Компани | Макроциклические ингибиторы белок/белковых взаимодействий pd-1/pd-l1 и cd80(b7-1)/pd-l1 |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US20180044304A1 (en) | 2015-03-10 | 2018-02-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
| KR102708045B1 (ko) | 2015-03-10 | 2024-09-23 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| BR112017019307A2 (pt) | 2015-03-10 | 2018-05-02 | Aurigene Discovery Technologies Limited | compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores |
| CU20170118A7 (es) | 2015-03-10 | 2018-02-08 | Aurigene Discovery Tech Ltd | Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores |
| BR112017019305A2 (pt) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos cíclicos terapêuticos como imunomoduladores |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10110466B2 (en) * | 2015-11-23 | 2018-10-23 | Tyco Electronics Subsea Communications Llc | Optical communication system with distributed wet plant manager |
| CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
-
2017
- 2017-04-06 CN CN201780034790.7A patent/CN109310677A/zh active Pending
- 2017-04-06 MX MX2018012132A patent/MX384929B/es unknown
- 2017-04-06 PT PT177798014T patent/PT3439653T/pt unknown
- 2017-04-06 JP JP2019503632A patent/JP7539231B2/ja active Active
- 2017-04-06 KR KR1020187032233A patent/KR102370704B1/ko active Active
- 2017-04-06 ES ES17779801T patent/ES2864148T3/es active Active
- 2017-04-06 BR BR112018070361A patent/BR112018070361A2/pt not_active Application Discontinuation
- 2017-04-06 DK DK17779801.4T patent/DK3439653T3/da active
- 2017-04-06 TW TW106111608A patent/TWI808938B/zh active
- 2017-04-06 WO PCT/US2017/026290 patent/WO2017176965A1/en not_active Ceased
- 2017-04-06 EP EP17779801.4A patent/EP3439653B1/en active Active
- 2017-04-06 US US15/480,992 patent/US10568870B2/en active Active
- 2017-04-06 IL IL261998A patent/IL261998B2/en unknown
- 2017-04-06 RU RU2018138828A patent/RU2745195C2/ru active
- 2017-04-06 PL PL17779801T patent/PL3439653T3/pl unknown
- 2017-04-06 SG SG11201808626WA patent/SG11201808626WA/en unknown
- 2017-04-06 AU AU2017246460A patent/AU2017246460B2/en active Active
- 2017-04-07 AR ARP170100898A patent/AR108202A1/es unknown
-
2018
- 2018-10-05 ZA ZA2018/06633A patent/ZA201806633B/en unknown
-
2020
- 2020-01-14 US US16/742,139 patent/US11744822B2/en active Active
-
2022
- 2022-06-07 JP JP2022092430A patent/JP7611189B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108202A1 (es) | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CL2020000856A1 (es) | Isoquinolinas como inhibidores de hpk1. (divisional solicitud 201902734) | |
| AR128748A2 (es) | Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX2016015436A (es) | Compuestos para tratar el cancer cerebral. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| AR101177A1 (es) | Inhibidores de la syk | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201890812A1 (ru) | Дополнительная терапия 25-гидроксивитамином d и изделия для этого | |
| EA201790745A1 (ru) | Трициклические соединения | |
| EA201591628A1 (ru) | Дейтерированный палбоциклиб | |
| EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний |